Observational Antiretroviral Studies In Southern Africa (OASIS) Collaboration

南部非洲观察性抗逆转录病毒研究 (OASIS) 合作

基本信息

批准号：
7500359
负责人：
Matthias Egger
金额：
$ 10.95万
依托单位：
UNIVERSITAT BERN
依托单位国家：
美国
项目类别：
财政年份：
2006
资助国家：
美国
起止时间：
2006-07-01 至 2011-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7500359
关键词：
Accounting Acquired Immunodeficiency Syndrome Adult Adverse event Africa Africa South of the Sahara African Age Anti-Retroviral Agents Area Arts Birth Botswana Characteristics Child Clinic Clinical Cohort Studies Collaborations Country Data Data Analyses Data Collection Death Rate Development Economics Effectiveness Epidemiologist Evaluation Exposure to HIV HIV-1 Health Services Research Healthcare Human Human Resources Immune Immunologic Deficiency Syndromes Individual Infant Mortality Infection Inflammatory Life Life Expectancy Live Birth Low income Malaria Malawi Measures Methods Monitor Mozambique National Institute of Allergy and Infectious Disease Opportunistic Infections Outcome Pharmaceutical Preparations Population Pregnant Women Prevalence Principal Investigator Prognostic Factor Prophylactic treatment Rate Research Research Design Services Site Source South Africa Southern Africa Structure Syndrome Techniques Time Training Tuberculosis United States National Institutes of Health Universities Vertical Disease Transmission Virus Virus Diseases Waiting Lists Woman World Health Organization Zambia Zimbabwe antiretroviral therapy cohort design experience follow-up improved innovation men outcome forecast prevent programs reconstitution response skills social

项目摘要

Rationale: Southern Africa is where almost 30% of the approximately 40 million HIV-infected people in the world live, in an area estimated to have 2% of the global population. While an estimated two million men, women, and children are yet in urgent need of antiretroviral treatment in this region, close to 200,000 individuals are now believed by the World Health Organization to be receiving treatment. Answers are urgently needed to clinical and operational research questions regarding the most effective implementation and monitoring of wide-scale antiretroviral treatment delivery. Specific Aims: 1) To measure the effectiveness of antiretroviral therapy in southern Africa, and to describe factors that influence outcomes; 2) To improve the prognosis of people living with HIV and AIDS eligible for or initiating highly active antiretroviral treatment in southern Africa through timely and operative regional epidemiological evaluations; and 3) To increase the capacity for delivering antiretroviral therapy in this region by increasing the capacity for monitoring exposures and outcomes at the individual and population levels. Research Objectives: 1) To describe issues related to the provision of health care to children and adults in southern Africa, with a focus on the delivery of ART, waiting times and program level influences on survival and other outcomes, including losses to follow up; 2) To describe antiretroviral treatment issues in adults (including pregnant women) and children, with an emphasis on the monitoring of treatment response and prognostic factors, including exposure to drugs to prevent mother to child transmission of HIV, and adverse events associated with antiretroviral treatment; and 3) To describe issues related to important complications of HIV infection and antiretroviral therapy use, with a focus on tuberculosis, the immune reconstitution and inflammatory syndrome, and prophylaxis against life-threatening opportunistic infections. Research Design and Methods: The OASIS Collaboration includes 17 clinics and clinical cohorts in 6 countries in the region, involving 35,070 HIV-1 infected adults and children. We will use innovative and state-of-the-art statistical approaches to analyze data from this observational cohort study, including techniques which account for the longitudinal and hierarchical structure of the data. An operational structure is proposed that emphasizes the long-term collaborative and capacity-building approach of the collaboration.

理由：南部非洲是该地区约 4000 万艾滋病毒感染者中近 30% 的地区。世界生活在估计拥有全球人口 2% 的地区。虽然估计有 200 万人，该地区仍有近 20 万名妇女和儿童迫切需要抗逆转录病毒治疗世界卫生组织目前认为个人正在接受治疗。答案是迫切需要有关最有效实施的临床和业务研究问题以及监测大规模抗逆转录病毒治疗的实施。具体目标： 1) 衡量南部非洲抗逆转录病毒治疗的有效性，并描述影响结果的因素； 2) 改善艾滋病毒感染者和符合条件的艾滋病患者的预后或通过及时有效的区域性治疗在南部非洲启动高度积极的抗逆转录病毒治疗流行病学评估； 3) 提高该地区提供抗逆转录病毒治疗的能力通过提高监测个人和人口层面的暴露和结果的能力。研究目标： 1) 描述与向儿童和成人提供医疗保健有关的问题南部非洲，重点关注抗逆转录病毒治疗的提供、等待时间和项目水平对生存的影响以及其他结果，包括后续损失； 2) 描述成人的抗逆转录病毒治疗问题（包括孕妇）和儿童，重点是监测治疗反应和预后因素，包括接触预防艾滋病毒母婴传播的药物以及不良反应与抗逆转录病毒治疗相关的事件； 3) 描述与重要并发症相关的问题 HIV 感染和抗逆转录病毒治疗的使用，重点关注结核病、免疫重建和炎症综合征和预防危及生命的机会性感染。研究设计和方法：OASIS 合作组织包括 17 个诊所和 6 个临床队列该地区国家，涉及 35,070 名 HIV-1 感染成人和儿童。我们将用创新和最先进的统计方法来分析这项观察性队列研究的数据，包括解释数据的纵向和层次结构的技术。运营结构建议强调长期合作和能力建设的合作方式。